Weight-loss peptides
GLP-1 and related metabolic research peptides — such as tirzepatide, semaglutide, and retatrutide — compared by independent third-party purity grades, reputation, and price. For research use only.
- CagrilintideB
A long-acting synthetic analog of amylin, a hormone co-secreted with insulin by pancreatic beta cells.
18 vendors graded - MazdutideA
An investigational dual GLP-1 / glucagon receptor agonist co-developed by Innovent Biologics and Eli Lilly.
10 vendors graded - RetatrutideA
An investigational triple agonist targeting GLP-1, GIP, and glucagon receptors, developed by Eli Lilly.
166 vendors graded - SemaglutideA
A long-acting GLP-1 receptor agonist developed by Novo Nordisk.
51 vendors graded - SurvodutideA
An investigational dual GLP-1 / glucagon receptor agonist developed by Boehringer Ingelheim and Zealand Pharma.
7 vendors graded - TirzepatideA
A dual GIP / GLP-1 receptor agonist developed by Eli Lilly.
138 vendors graded